Chan C. Whiting

1.4k total citations
32 papers, 823 citations indexed

About

Chan C. Whiting is a scholar working on Genetics, Surgery and Immunology. According to data from OpenAlex, Chan C. Whiting has authored 32 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Surgery and 9 papers in Immunology. Recurrent topics in Chan C. Whiting's work include Diabetes and associated disorders (9 papers), Cancer Research and Treatments (8 papers) and Pancreatic function and diabetes (8 papers). Chan C. Whiting is often cited by papers focused on Diabetes and associated disorders (9 papers), Cancer Research and Treatments (8 papers) and Pancreatic function and diabetes (8 papers). Chan C. Whiting collaborates with scholars based in United States, France and Ukraine. Chan C. Whiting's co-authors include Saroja Ramanujan, Lisl K.M. Shoda, Huub T. C. Kreuwel, Mark A. Atkinson, Jeffrey A. Bluestone, Diane Mathis, Daniel L. Young, C. Garrison Fathman, George S. Eisenbarth and Richard Kahn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Immunity.

In The Last Decade

Chan C. Whiting

32 papers receiving 791 citations

Peers

Countries citing papers authored by Chan C. Whiting

Since Specialization

Citations

This map shows the geographic impact of Chan C. Whiting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chan C. Whiting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chan C. Whiting more than expected).

Fields of papers citing papers by Chan C. Whiting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chan C. Whiting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chan C. Whiting. The network helps show where Chan C. Whiting may publish in the future.

Co-authorship network of co-authors of Chan C. Whiting

This figure shows the co-authorship network connecting the top 25 collaborators of Chan C. Whiting. A scholar is included among the top collaborators of Chan C. Whiting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chan C. Whiting. Chan C. Whiting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors 2024 ·Cancer Research Communications ·Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana Crysler, Pamela N. Münster, Meredith McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, (unknown), Peppi Prasit, (unknown), Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan	11
2	Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors 2023 ·Cancer Research Communications ·Brian J. Francica, Anja Holtz, Justine Lopez, David Freund, (unknown), Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. DuBois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky	20
3	Abstract 1333: Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway 2022 ·Cancer Research ·Brian J. Francica, Justine Lopez, Anja Holtz, (unknown), Dingzhi Wang, Amanda Enstrom, Raymond N. DuBois, (unknown), Dipak Panigrahy, Chan C. Whiting, Sam H. Whiting, Thomas W. Dubensky	1
4	Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer 2020 ·Cancer Immunology Research ·Nitya Nair, (unknown), Ed Lemmens, Serena Chang, Dung T. Le, Elizabeth M. Jaffee, Aimee Murphy, Chan C. Whiting, Thomas Müller, Dirk G. Brockstedt	17
5	Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma 2019 ·Clinical Cancer Research ·Raffit Hassan, Evan Alley, Hedy L. Kindler, Scott Antonia, Thierry Jahan, Somayeh Honarmand, Nitya Nair, Chan C. Whiting, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Gina Choe, Anish Thomas, (unknown), Aimee Murphy, Elizabeth M. Jaffee, Lisa M. Coussens, Dirk G. Brockstedt	88
6	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). 2017 ·Journal of Clinical Oncology ·Dung T. Le, Andrew H. Ko, Zev A. Wainberg, Vincent J. Picozzi, Hedy L. Kindler, Andrea Wang‐Gillam, Paul E. Oberstein, Michael A. Morse, Herbert J. Zeh, Colin D. Weekes, Tony R. Reid, Aimee Murphy, (unknown), Chan C. Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee	39
7	208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial 2016 ·Journal of Thoracic Oncology ·Thierry Jahan, Raffit Hassan, Evan Alley, Hedy L. Kindler, Scott Antonia, Chan C. Whiting, Lisa M. Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt	11
8	Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer. 2016 ·Journal of Clinical Oncology ·Dung T. Le, Chan C. Whiting, Eric R. Lutz, Nitya Nair, Amanda Engstrom, Ed Lemmens, (unknown), Aimee Murphy, Dirk G. Brockstedt, Elizabeth M. Jaffee	3
9	CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). 2016 ·Journal of Clinical Oncology ·Raffit Hassan, Evan Alley, Hedy L. Kindler, Scott Antonia, Thierry Jahan, Somayeh Honarmand, (unknown), Chan C. Whiting, Nitya Nair, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Lisa M. Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt	2
10	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy 2015 ·Arthritis Research & Therapy ·Nitya Nair, Henrik E. Mei, Shih‐Yu Chen, Matthew B. Hale, Garry P. Nolan, Holden T. Maecker, Mark C. Genovese, C. Garrison Fathman, Chan C. Whiting	44
11	Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival. 2015 ·Journal of Clinical Oncology ·Chan C. Whiting, Eric R. Lutz, Nitya Nair, Serena Chang, Ed Lemmens, (unknown), Sara Solt, Sandy Ferber, Holden T. Maecker, Aimee Murphy, Dirk G. Brockstedt, Elizabeth M. Jaffee, Dung T. Le	9
12	Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging 2015 ·PLoS ONE ·Chan C. Whiting, Janet Siebert, Aaron M. Newman, (unknown), Ash A. Alizadeh, Jörg J. Goronzy, Cornelia M. Weyand, Eswar Krishnan, C. Garrison Fathman, Holden T. Maecker	76
13	Inflammation and Hyperglycemia Mediate Deaf1 Splicing in the Pancreatic Lymph Nodes via Distinct Pathways During Type 1 Diabetes 2014 ·Diabetes ·Linda Yip, (unknown), Cariel Taylor, Rémi J. Creusot, (unknown), Chan C. Whiting, Jill Schartner, Rahima Akter, Matthias von Herrath, C. Garrison Fathman	18
14	Diminished Adenosine A1 Receptor Expression in Pancreatic α-Cells May Contribute to the Pathology of Type 1 Diabetes 2013 ·Diabetes ·Linda Yip, Cariel Taylor, Chan C. Whiting, C. Garrison Fathman	36
15	The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse 2010 ·Clinical & Experimental Immunology ·Lisl K.M. Shoda, Huub T. C. Kreuwel, Kapil Gadkar, Yanan Zheng, Chan C. Whiting, Mark A. Atkinson, Jeffrey A. Bluestone, Diane Mathis, David Young, Saroja Ramanujan	43
16	Sa.66. In Silico Modeling of Intranasal Insulin B:9-23 Peptide Therapy in the Non-Obese Diabetic (NOD) Mouse: Mechanisms of Action, Protocol Optimization, and Implications for Clinical Trial Design 2008 ·Clinical Immunology ·Jason R. Chan, Yanan Zheng, Georgia Fousteri, Matthias von Herrath, Chan C. Whiting	1
17	Dosing and Timing Effects of Anti‐CD40L Therapy 2007 ·Annals of the New York Academy of Sciences ·Kapil Gadkar, Lisl K.M. Shoda, Huub T. C. Kreuwel, Saroja Ramanujan, Yanan Zheng, Chan C. Whiting, Daniel L. Young	9
18	The Virtual NOD Mouse 2007 ·Annals of the New York Academy of Sciences ·Yanan Zheng, Huub T. C. Kreuwel, Daniel L. Young, Lisl K.M. Shoda, Saroja Ramanujan, Kapil Gadkar, Mark A. Atkinson, Chan C. Whiting	7
19	Mechanisms Mediating Anti‐CD3 Antibody Efficacy 2006 ·Annals of the New York Academy of Sciences ·Daniel L. Young, Saroja Ramanujan, Huub T. C. Kreuwel, Chan C. Whiting, Kapil Gadkar, Lisl K.M. Shoda	4
20	A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation 2005 ·Immunity ·Lisl K.M. Shoda, Daniel L. Young, Saroja Ramanujan, Chan C. Whiting, Mark A. Atkinson, Jeffrey A. Bluestone, George S. Eisenbarth, Diane Mathis, Aldo A. Rossini, Scott E. Campbell, Richard Kahn, Huub T. C. Kreuwel	242

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact